切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2019, Vol. 08 ›› Issue (03) : 227 -230. doi: 10.3877/cma.j.issn.2095-3224.2019.03.003

所属专题: 文献

青年专家论坛

直肠胃肠间质瘤的临床病理特征和治疗
张信华1,()   
  1. 1. 中山大学附属第一医院胃肠外科中心
  • 收稿日期:2018-10-17 出版日期:2019-06-25
  • 通信作者: 张信华
  • 基金资助:
    广东省科技计划(No.2016A020213002)

Pathoclinical characteristic and treatment of rectal gastrointestinal stromal tumors (GISTs)

Xinhua Zhang1,()   

  1. 1. Department of Gastrointinal Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
  • Received:2018-10-17 Published:2019-06-25
  • Corresponding author: Xinhua Zhang
  • About author:
    Corresponding author: Zhang Xinhua, Email:
引用本文:

张信华. 直肠胃肠间质瘤的临床病理特征和治疗[J/OL]. 中华结直肠疾病电子杂志, 2019, 08(03): 227-230.

Xinhua Zhang. Pathoclinical characteristic and treatment of rectal gastrointestinal stromal tumors (GISTs)[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(03): 227-230.

直肠是胃肠间质瘤的第三常见部位,其临床病理学特征、生物学行为和解剖部位使其诊治具有特殊性。好发于直肠中下段且术后局部复发率偏高,都是直肠GIST治疗的难点。伊马替尼的围手术期治疗增加了手术切除率并降低了复发率,5 cm以下的直肠GIST靶向治疗联合手术切除治疗效果较好。目前,国内外尚缺少直肠GIST的诊疗规范,未来还需要更多的前瞻性多中心研究进一步探讨并得出结论。

Rectum is the third most common site GISTs originise from. The management of rectal GISTs holds characteristics and difficulty owing to biology and anatomical location. They tending to occur in lower rectum with relatively high local recurrence rate. The application of peri-operational imatinib increase the resectability of tumor and lower recurrence rate. For rectal GIST with diameter of less than 5 cm, imatinib combined surgical resection can achieve a good therapeutic effect. At present, there is still lack of standard of diagnosis and treatment for rectal GIST worldwide. More prospective multicenter studies are needed for better understanding and management of this special entity.

[1]
Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing [J]. PLoS One, 2011, 6(8): e20294.
[2]
Ma GL, Murphy JD, Martinez ME, et al. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study [J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(1): 298-302.
[3]
Kukar M, Kapil A, Papenfuss W, et al. Gastrointestinal stromal tumors (GISTs) at uncommon locations: a large population based analysis [J]. J Surg Oncol, 2015, 111(6): 696-701.
[4]
Yasui M, Tsujinaka T, Mori M, et al. Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data [J]. Surg Today, 2017, 47(10): 1188-1194.
[5]
Changchien CR, Wu MC, Tasi WS, et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immmunohistochemical stanning [J]. Dis Colon Rctum, 2004, 47(11): 1922-1929.
[6]
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites [J]. Semin Diagn Pathol, 2006, 23(2): 70-83.
[7]
Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation [J]. Appl Immunohistochem Mol Morphol, 2005, 13(3): 205-220.
[8]
Hawkins A, Wells K, Krishnamurty D, et al. Preoperative Chemotherapy and Survival for Large Anorectal Gastrointestinal Stromal Tumors: A National Analysis of 333 Cases [J]. Ann Surg Oncol, 2017, 24(5): 1195-1201.
[9]
Cavnar, M, Wang L, Balachandran V, et al. Rectal Gastrointestinal Stromal Tumor (GIST) in the era of imatinib: Organ preservation and improved oncologic O\outcome [J]. Ann Surg Oncol, 2017, 24(13): 3972-3980.
[10]
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors [J]. J Clin Oncol, 2004, 22(18): 3813-3825.
[11]
Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts [J]. Lancet Oncol, 2012, 13(3): 265-274.
[12]
周维霞, 丁科枫,殷国建, 等. 超声内镜对结直肠黏膜下病变的诊断价值[J]. 中国内镜杂志, 2017, 23(6): 92-97.
[13]
Li J, Ye Y, Wang J, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor [J]. Chin J Cancer Res, 2017, 29(4): 281-293.
[14]
DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J]. Lancet, 2009, 373(9669): 1097-1104.
[15]
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial [J]. JAMA, 2012, 307(12): 1265-1272.
[16]
Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor [J]. Eur J Surg Oncol, 2011, 37(4): 319-324.
[17]
Huynh TK, Meeus P, Cassier P, et al. Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma Group[J]. BMC Cancer, 2014, 14: 156.
[18]
Liu H, Yan Z, Liao G, et al. Treatment strategy of rectal gastrointestinal stromal tumor (GIST) [J]. J Surg Oncol, 2014, 109(7): 708-713.
[19]
Wilkinson MJ, Fitzgerald JE, Strauss DC, et al. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib [J]. Br J Surg, 2015, 102(8): 965-971.
[20]
Jakob J, Mussi C, Ronellenfitsch U, et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib [J]. Ann Surg Oncol, 2013, 20(2): 586-592.
[21]
Pai VD, Demenezes JL, Patil PS, et al. Multimodality therapy of rectal gastrointestinal stromal tumors in the era of imatinib: an Indian series [J]. J Gastrointest Oncol, 2016, 7(2): 262-268.
[22]
Tielen R, Verhoef C, van Coevorden F, et al. Surgical management of rectal gastrointestinal stromal tumors [J]. J Surg Oncol, 2013, 107(4): 320-323.
[23]
中华医学会外科学分会胃肠外科学组. 胃肠间质瘤规范化外科治疗专家共识[J]. 中国实用外科杂志, 2015, 35(6): 593-597.
[24]
中华医学会外科学分会结直肠外科学组,中华医学会外科学分会腹腔镜与内镜外科学组. 直肠癌经肛全直肠系膜切除专家共识及手术操作指南(2017版) [J]. 中国实用外科杂志, 2017, 37(9): 978-984.
[1] 王振宁, 杨康, 王得晨, 邹敏, 归明彬, 王雅楠, 徐明. 机器人与腹腔镜手术联合经自然腔道取标本对中低位直肠癌患者远期疗效比较[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 437-442.
[2] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[3] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[4] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[5] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[6] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径<1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[7] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[8] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[11] 王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
[12] 孙晗, 于冰, 武侠, 周熙朗. 基于循环肿瘤DNA 甲基化的结直肠癌筛查预测模型的构建与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 500-506.
[13] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[14] 王湛, 李文坤, 杨奕, 徐芳, 周敏思, 苏珈仪, 王亚丹, 吴静. 炎症指标在早发性结直肠肿瘤中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 802-810.
[15] 刘福成, 赵欣, 乔海朋, 刘晓峰, 张翀, 张宗明. 保留左结肠动脉的肠系膜下动脉根部淋巴结清扫对腹腔镜直肠癌根治术的疗效影响[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 647-653.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?